COMMUNIQUÉS West-GlobeNewswire

PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors
20/10/2026
John Dawson CBE, Deborah Ramsdell and Bruce Wendel bring corporate development, commercialization, and regulatory experience to the Company as it advances PDS0301 toward Phase 3 trial in Metastatic Colorectal Cancer ( [...]
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer
20/10/2026
REDWOOD CITY, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for [...]
Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast
20/10/2026
Investor webcast at 4:30 p.m. ET on October 22 to discuss ORIGIN 3 final efficacy results for TRUTAKNA ™ (atacicept-vymj) featured in a late-breaking oral presentation during the opening plenary session of ASN Kidney [...]
InnovAge to Announce Fiscal First Quarter 2027 Financial Results and Host Conference Call Tuesday, November 3, 2026
20/10/2026
DENVER, Oct. 20, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible [...]
Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026
20/10/2026
CHARLESTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac [...]
BioVie Presents Data on Bezisterim in Parkinson’s Disease at the 2026 American Neurological Association Annual Meeting
20/10/2026
Parkinson’s patients elevated baseline inflammation demonstrated statistically significant improvements in both motor and non-motor symptoms with Bezisterim compared to placebo. CARSON CITY, Nev., Oct. 20, 2026 (GLOBE [...]
Biomolecular Holdings Announces Issuance of Foundational Patent for Revolutionary Dimeric Fusion Protein Technology
20/10/2026
BURLINGAME, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Biomolecular Holdings LLC, a privately held biotechnology company advancing next-generation antibody architectures, today announced that the United States Patent and [...]
Alignment Health Plan Recognized Among U.S. News & World Report’s 2027 Best Insurance Companies for Medicare Advantage
20/10/2026
Alignment earns “Best” rating in Arizona, California, Nevada, North Carolina and Texas for the second consecutive year, reflecting strong performance in care quality, prevention and satisfaction ORANGE, Calif., Oct. 20 [...]
Stereotaxis to Report Third Quarter 2026 Financial Results on November 10, 2026
20/10/2026
ST. LOUIS, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release [...]
Medicovestor Announces FDA Fast Track Designation for MC001, Its First-in-Class Chemoimmunotherapy ADC for Pancreatic Cancer
20/10/2026
Designation follows recent IND activation and builds on Orphan Drug Designation granted in 2025. NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Medicovestor, Inc. today announced that the US Food and Drug Administration ( [...]
The Consortium for Top-Down Proteomics is now The Proteoform Alliance, with the Expanded Mission to Unlock the Full Potential of Proteoform Biology
20/10/2026
Proteoforms are the primary effectors of biological function, and uniting the various technologies, applications, and institutions in one organization will greatly increase our knowledge and capabilities for proteoform- [...]
Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026
20/10/2026
Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on [...]
Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call
20/10/2026
BOSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases [...]
Kane Biotech Signs Distribution Agreement with The Stevens Company
20/10/2026
Expands Kane Biotech’s commercial footprint and access to the revyve ® product line across Canada WINNIPEG, Manitoba, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane [...]
Mammogen Names National Cancer Screening Leader, Dr. Rebecca Kaltman, to Lead Pivotal genTRU-breast™ Study
20/10/2026
Executive Director of the Inova Saville Cancer Screening and Prevention Center will lead KATELYN-ERIN, Mammogen’s large prospective study evaluating its blood-based RNA assay to support breast cancer detection NEWPORT [...]
PolarityBio Highlights Highest Scoring Abstract Award and Presentation of Phase 3 COVER DFUS II Trial Results at SAWC Fall 2026
20/10/2026
“Autologous Cutaneous Multicellular Units in Non-Healing Wagner 1 Diabetic Foot Ulcers: Results of the Phase 3 COVER DFUS II Trial” honored with top award in Clinical Research category Pivotal Phase 3 trial met primary [...]
Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026
20/10/2026
85% year-over-year scan volume growth in Q3 2026, contributing to 117% growth for the nine months ended September 30, 2026 European Spine Journal publishes peer-reviewed data supporting MRS as a potential viable [...]
Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026
20/10/2026
Correlation between clinical efficacy and changes in inflammatory biomarkers, mucosal transcriptomic signatures, and histologic disease activity strengthens the previously shown clinical proof of concept for OD-001 [...]
Slate Medicines Strengthens Board of Directors with Appointment of Stephen K. Brannan, MD, and John D. Young
20/10/2026
RALEIGH, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Slate Medicines, Inc. (“Slate”), a clinical-stage biotechnology company committed to advancing innovative new therapies that may broaden the treatment paradigm and [...]

Pages